At close: July 23 at 9:00:00 PM GMT+1
Key Executives
Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in SEK.
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Staffan Stromberg Ph.D. | Chief Exec. Officer | 6.28M | -- | 1967 |
| Mr. Robert Molander | Chief Commercial Officer | 63k | -- | 1965 |
| Ms. Maria Ekdahl | Chief Financial Officer | -- | -- | 1973 |
| Mr. Anders Kronström | Chief Operating Officer | -- | -- | 1967 |
| Prof. Jonas Rastad M.D., Ph.D. | Chief Medical Officer & Chief Scientific Officer | -- | -- | 1950 |
Infant Bacterial Therapeutics AB (publ)
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 8
Description
Infant Bacterial Therapeutics AB (publ), a clinical stage pharmaceutical company, develops drugs to prevent or treat rare diseases affecting premature infants in Sweden. The company's lead drug candidate is IBP-9414, to prevent necrotizing enterocolitis, as well as to improve feeding tolerance affecting premature infants. It is also developing IBP-1016 for the treatment of gastroschisis, a rare and severe disease in infants. The company was incorporated in 2011 and is based in Stockholm, Sweden.
Corporate Governance
Infant Bacterial Therapeutics AB (publ)’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Upcoming Events
February 6, 2025 at 7:30 AM UTC - February 10, 2025 at 7:30 AM UTC
Infant Bacterial Therapeutics AB (publ) Earnings Date
Recent Events
Recent Events Information Not Available